From alcohol to 1,2,3-triazole via multi-step continuous-flow synthesis of rufinamide precursor
Green Chem., 2016, Accepted ManuscriptDOI: 10.1039/C6GC01133K, PaperSvetlana Borukhova, Timothy Noel, Bert Metten, Eric De Vos, Volker HesselRufinamide is an antiepileptic drug used to treat the Lennox-Gastaut syndrome. It comprises a relatively simple molecular structure. Rufinamide can be synthesized from an organohalide in three steps. Recently we...The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Green Chem. latest articles)
Source: RSC - Green Chem. latest articles - May 27, 2016 Category: Chemistry Authors: Svetlana Borukhova Source Type: research
Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report
Publication date: Available online 19 April 2016 Source:Seizure Author(s): A.G.B. Thompson, H.R. Cock (Source: Seizure)
Source: Seizure - April 19, 2016 Category: Neurology Source Type: research
Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report
Rufinamide (RUF) is a novel antiepileptic agent that has entered clinical use within the last 10 years, thought to act through modulation of sodium channel activity[1]. (Source: Seizure: European Journal of Epilepsy)
Source: Seizure: European Journal of Epilepsy - April 18, 2016 Category: Neurology Authors: A.G.B. Thompson, H.R. Cock Tags: Clinical letter Source Type: research
A Life-Course Assessment of Treatment Patterns and Healthcare Costs of Lennox-Gastaut Syndrome (LGS) (P1.085)
Conclusions: LGS has a lifelong impact on patients, amassing greater total healthcare and medical costs from childhood through adulthood than all epilepsy patients. LGS-specific AEDs are underutilized in LGS patients. Increased clinical attention to LGS beyond pediatric years is warranted. Funding: Lundbeck, LLCDisclosure: Dr. Montouris has received personal compensation for activities with Lundbeck Research USA, Inc. Acorda Therapeutics, Eisai Inc. for serving on the advisory board member. Dr. Pina-Garza has received personal compensation for activities with Eisai Inc. as a consultant. Dr. Vekeman has nothing to disclose...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Montouris, G., Piňa-Garza, J. E., Vekeman, F., Cheng, W., Tuttle, E., Giguere-Duval, P., Duh, M. S., Shen, V., Isojarvi, J. Tags: Epilepsy/Clinical Neurophysiology: Geriatric Epilepsy, Epidemiology, and Health Services Source Type: research
Response Durability Analyses from a Rufinamide Pivotal Trial in Lennox-Gastaut Syndrome (LGS) (P2.043)
Conclusions: There was no evidence of tolerance to rufinamide during short-term and long-term treatment. These data support adjunctive rufinamide treatment for multiple seizure types, which may enhance patient adherence. Refs:1Loscher.Epilepsia2006;47:1253-84. Support: Eisai Inc.Disclosure: Dr. Ng has nothing to disclose. Dr. Glauser has received (royalty or license fee or contractual rights) payments from AssureRx Health. Dr. Ferreira has received personal compensation for activities with Eisai Inc. Dr. Olhaye has received personal compensation for activities with Eisai Inc., as an employee. Dr. Williams has received pe...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Ng, Y.-t., Glauser, T., Ferreira, J., Olhaye, O., Williams, B., Perdomo, C., Bibbiani, F. Tags: Epilepsy/Clinical Neurophysiology: AEDs Source Type: research
Efficacy of Rufinamide as Adjunctive Treatment for Adults With Lennox-Gastaut Syndrome: Subgroup Analysis From a Phase III Trial (P2.056)
Conclusions: Rufinamide demonstrated favourable efficacy, compared with placebo, when used as adjunctive treatment for adults with LGS. Ref: 1Arzimanoglou et al. Lancet.2009;8(1):82-93. Support: Eisai Inc.Disclosure: Dr. Striano has received personal compensation for activities with Shire Pharma and Eisai Inc. Dr. McMurray has received personal compensation for activities with Eisai Ltd. as an employee. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Striano, P., McMurray, R. Tags: Epilepsy/Clinical Neurophysiology: AEDs Source Type: research
Rufinamide in children and adults in routine clinical practice
ConclusionsRufinamide was well tolerated and was effective in reducing frequency of generalized tonic–clonic, tonic/atonic and focal seizures in both children and adults with severe refractory epilepsies, primarily LGS. (Source: Acta Neurologica Scandinavica)
Source: Acta Neurologica Scandinavica - February 29, 2016 Category: Neurology Authors: S. Jaraba, E. Santamarina, J. Miró, M. Toledo, A. Molins, J. Burcet, J. L. Becerra, M. Raspall, G. Pico, E. Miravet, A. Cano, P. Fossas, S. Fernández, M. Falip Tags: Original Article Source Type: research
Aggravation of atonic seizures by rufinamide: A case report
Rufinamide is a novel antiepileptic drug used as adjunctive therapy in patients with Lennox–Gastaut syndrome and provides seizure control especially in tonic and atonic seizures. Rufinamide is expected to be effective in intractable epilepsy when atonic and tonic seizures exist. However, rufinamide induced seizure aggravation has been reported in a few patients, which was not associated with a specific type of seizure. (Source: Brain and Development)
Source: Brain and Development - February 21, 2016 Category: Neurology Authors: Gonca Bektaş, Mine Çalışkan, Ali Aydın, Edibe Pembegül Yıldız, Burak Tatlı, Nur Aydınlı, Meral Özmen Tags: Case Report Source Type: research
Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics
Publication date: Available online 16 February 2016 Source:Pharmacological Research Author(s): Edoardo Spina, Francesco Pisani, Jose de Leon Antiepileptic drugs (AEDs) are frequently co-prescribed with new antidepressants (ADs) or new antipsychotics (APs). A PubMed search with no time limit was used to update the review of the clinically significant pharmacokinetic (PK) drug interactions DIs (DIs) between AEDs with new ADs and APs. Our best interpretation of what to expect regarding dosing changes in the average patient after combining AEDs with new ADs or new APs is summarized on updated tables that integrate th...
Source: Pharmacological Research - February 17, 2016 Category: Drugs & Pharmacology Source Type: research
Life cycle assessment of multi-step rufinamide synthesis - from isolated reactions in batch to continuous microreactor networks
Green Chem., 2016, 18,1096-1116DOI: 10.1039/C5GC01932J, PaperDenise Ott, Svetlana Borukhova, Volker HesselRufinamide is an antiepileptic drug to treat Lennox-Gastaut syndrome, in combination with other medications. Herein, several batch and continuous process routes to rufinamide are analysed and optimised regarding their environmental impact, to finally predict a fully continuous, telescoped process route.The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Green Chem. latest articles)
Source: RSC - Green Chem. latest articles - February 15, 2016 Category: Chemistry Authors: Denise Ott Source Type: research
Treatment of Adults with Lennox–Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide
Conclusion
Rufinamide demonstrated favorable efficacy and was generally well tolerated when used as adjunctive treatment for adults with LGS.
Funding
Eisai. (Source: Neurology and Therapy)
Source: Neurology and Therapy - February 10, 2016 Category: Neurology Source Type: research
Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial
Lennox-Gastaut syndrome (LGS) is an epileptic encephalopathy characterized by various types of epileptic seizures (mainly tonic seizures), diffuse slow spike-and-wave complex patterns on the electroencephalogram (EEG), and impairment of cognitive function. The long-term prognosis for mental function and seizures is generally devastating (Arzimanoglou et al., 2009; Beaumanoir, 1985; Blatter-Arifi, 1991; Oguni et al., 1996; Ohtsuka et al., 1990; Yagi, 1996). A high risk of sudden falls due to tonic and/or atonic seizures often affects the quality of life. (Source: Epilepsy Research)
Source: Epilepsy Research - January 12, 2016 Category: Neurology Authors: Yoko Ohtsuka, Harumi Yoshinaga, Yukiyoshi Shirasaka, Rumiko Takayama, Hiroki Takano, Kuniaki Iyoda Source Type: research
Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
Abstract
OBJECTIVE: A good knowledge of safety and age group-specific pharmacokinetics (PK) of antiepileptic drugs (AEDs) in young pediatric patients is of great importance in clinical practice. This paper presents 6-month interim safety and PK from an ongoing 2-year open-label study (Study 303) of adjunctive rufinamide treatment in pediatric subjects ≥1 to <4 years with inadequately controlled epilepsies of the Lennox-Gastaut syndrome (LGS) spectrum.
METHODS: Subjects (N = 37) were randomized to either rufinamide or any other approved AED chosen by the investigator as adjunctive therapy to ...
Source: European Journal of Paediatric Neurology - January 11, 2016 Category: Neurology Authors: Arzimanoglou A, Ferreira JA, Satlin A, Mendes S, Williams B, Critchley D, Schuck E, Hussein Z, Kumar D, Dhadda S, Bibbiani F Tags: Eur J Paediatr Neurol Source Type: research
The efficacy and safety of rufinamide in drug-resistant epilepsy: A meta-analysis of double-blind, randomized, placebo controlled trials
Epilepsy is one of the most common types of human neurological disorder, and 30% of patients with epilepsy continue to seizure, despite tailored medical therapy (drug-resistant epilepsy) (Bialer and White, 2010). Although surgical resection of the epileptic focus may abolish epileptic seizures, many individuals are poor surgical candidates because of multifocal seizure origin or the epileptic focus being near the eloquent cortex (Berg, 2011; Wiebe, 2014). Moreover, about one third of patients, who seem seizure free after surgical therapy will resume seizures in 3-5 years (Salanova et al., 2002; Tellez-Zenteno et al., 2005;...
Source: Epilepsy Research - January 7, 2016 Category: Neurology Authors: Zhenghao Xu, Huawei Zhao, Zhong Chen Source Type: research
Differential effects of sodium channel blockers on in vitro induced epileptiform activities.
Abstract
Antiepileptic drugs act on voltage gated sodium channels in many different ways: rufinamide is thought to influence the fast inactivation, so its anticonvulsant action could be similar to carbamazepine, whereas lacosamide enhances the slow inactivation; however some antidepressants were also described to act in the same way. Rufinamide, lacosamide, carbamazepine, fluoxetine and imipramine were tested using in vitro models of epileptiform activities. Extracellular local field potentials were recorded using hippocampal slices from immature rats and the pattern of epileptiform activities was analyzed...
Source: Archives of Pharmacal Research - October 29, 2015 Category: Drugs & Pharmacology Authors: Gáll Z, Orbán-Kis K, Szilágyi T Tags: Arch Pharm Res Source Type: research
